Pfizer (PFE) Stock Plummets 4%: PFE Is Doing An Important Step Forward The Goal Of Comprehensive Immunization Against RSV

Over the past 5 days, the value of the stock has been decreasing every day, not counting temporary and small ups. The price dropped from $ 48.02 to $ 47.15 last Thursday. In a day it traded at $ 46.43, which is 3% less than in the first half of the day on August 26. On Monday, the cost rose to $ 47.11, but after a while fell by $ 0.5. On Tuesday, it temporarily surged to $ 47.08. On the morning of September 1, the worth dropped to its lowest price of an entire week at $ 45.59. But now the value has improved slightly and is trading at $ 46.03.
RSV is a major cause of severe respiratory illness in older people and can lead to disability and death. There is a serious unmet medical need for an effective vaccine that can help protect the elderly from this highly infectious disease. Pfizer (PFE) declared the start of a clinical trial RENOIR, a Phase 3 clinical trial evaluating the efficacy, immunogenicity, and safety of a single dose of its respiratory syncytial virus (RSV), a bivalent perfusion F-subunit vaccine candidate (RSVpreF) in adults 60 years or older. The beginning of the Phase 3 study is an important step towards the goal of a comprehensive immunization against RSV.

Robert McDowney

Author

Get Hot Stocks Daily    Yes, Notify Me! No thanks